The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Enhancement of docetaxel efficacy by zoledronic acid pretreatment in docetaxel-resistant prostate cancer cells (PC-3/R and DU-145/R).
Zeki Surmeli
No relevant relationships to disclose
Emir Bozkurt
No relevant relationships to disclose
Ozge Ozer
No relevant relationships to disclose
Harika Atmaca
No relevant relationships to disclose
Asli Kisim
No relevant relationships to disclose
Selim Uzunoglu
No relevant relationships to disclose
Ruchan Uslu
No relevant relationships to disclose
Burcak Karaca
No relevant relationships to disclose